Akebia Therapeutics, Inc. revised revenue guidance for the year 2023. The company slightly lowered Auryxia net product revenue guidance to $170 million - $175 million for 2023 from $175 million - $180 million due to an unfavorable impact from market dynamics, volume and payor mix.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 USD | +0.88% | -4.96% | -7.26% |
05-09 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.26% | 239M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics, Inc. Revises Revenue Guidance for the Year 2023